The Danish pharmaceutical company Novo Nordisk has reported record profits of £4.5 billion for the first half of this year. The company attributes this increase to the high demand for its weekly semaglutide jabs, which have been praised by celebrities such as Elon Musk and Jeremy Clarkson. These jabs have been proven to aid weight loss by suppressing appetite, with overweight patients losing up to 21lbs in just over a year. Novo Nordisk states that doctors are now prescribing the drug to more patients than ever before. However, the global demand for these jabs has resulted in supply issues, prompting the company to restrict supplies in the US and prepare for the launch of the drug in the UK under the brand name Wegovy. Semaglutide works by mimicking a hormone released after eating, which suppresses appetite and reduces calorie intake. Novo Nordisk’s financial report also reveals a significant increase in sales for their GLP-1 diabetes drugs, highlighting the growing demand for treatments for obesity and diabetes. Novo Nordisk’s CEO emphasizes the importance of treating obesity as a chronic disease and highlights the positive impact that semaglutide can have on weight-related conditions. A recent study has also shown that taking Wegovy can reduce the risk of heart attacks and strokes in overweight or obese adults. While the drug has proven effective in aiding weight loss, it does come with side effects such as headaches, vomiting, and diarrhea. Despite its success, experts caution that it is not a miracle solution and users may regain weight once they stop taking the drug. The UK’s medicines watchdog has approved Wegovy for use in individuals with weight-related conditions and a BMI of 30 or higher. However, off-label prescribing for weight loss purposes is discouraged to ensure that diabetes patients have access to the medication. Novo Nordisk will continue to limit supplies of Wegovy in the US to meet the needs of existing patients.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
